# A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

> **NCT01129531** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 294 (actual)

## Conditions studied

- Neuralgia, Postherpetic

## Interventions

- **DRUG:** AGN-214868
- **DRUG:** Placebo to AGN-214868

## Key facts

- **NCT ID:** NCT01129531
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-10
- **Final completion:** 2012-01
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2013-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129531, "A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01129531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*